重组人肝细胞生长因子质粒治疗慢性肢体威胁性缺血患者:系统评价与Meta分析
该系统评价与Meta分析纳入7项随机对照研究共655例慢性肢体威胁性缺血(CLTI)患者,评估重组人肝细胞生长因子(HGF)质粒的疗效。低确定性证据显示,HGF治疗组完全溃疡愈合率显著高于安慰剂组(RR 1.99,95%CI 1.30-3.04;p=.002),且三个月随访时疼痛VAS评分较安慰剂组降低(MD -1.56,95%CI -2.12至-1.00;p<.001)。大截肢、全因死亡率及六个月踝肱指数变化两组间无显著差异。
要点
- 低确定性证据显示HGF质粒组完全溃疡愈合率显著高于安慰剂组(RR 1.99,95%CI 1.30-3.04;p=.002)。
- 三个月随访时HGF组疼痛VAS评分较安慰剂组降低(MD -1.56,95%CI -2.12至-1.00;p<.001),低确定性证据。
- 大截肢(RR 0.91,95%CI 0.48-1.73;p=.77)与全因死亡率(RR 0.93,95%CI 0.38-2.27;p=.87)两组间无显著差异,低确定性证据。
核心结论
- 低确定性证据提示,HGF治疗与CLTI患者完全溃疡愈合率提高及缺血性疼痛减轻相关。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE、Embase、Cochrane系统评价数据库及ClinicalTrials.gov,纳入评估HGF质粒疗效的随机对照研究。
- 共纳入7项研究,655例参与者。
- 对报告的相对风险(RR)或均数差(MD)进行Meta分析,并进行亚组分析以确定排除Buerger病队列中HGF质粒的疗效,同时评估各结局的证据确定性。
主要发现
- 基于低确定性证据,HGF治疗组完全溃疡愈合率显著高于安慰剂组(RR 1.99,95%CI 1.30-3.04;p=.002)。
- 三个月随访时,HGF组疼痛严重程度VAS评分较安慰剂组降低(MD -1.56,95%CI -2.12至-1.00;p<.001),低确定性证据。
- 大截肢率(RR 0.91,95%CI 0.48-1.73;p=.77)与全因死亡率(RR 0.93,95%CI 0.38-2.27;p=.87)在HGF组与安慰剂组间无显著差异,低确定性证据。
- 六个月时踝肱指数变化在HGF组与安慰剂组间无显著差异(MD 0.00,95%CI -0.09-0.09;p=1.0),低确定性证据。
- 亚组分析中,完全溃疡愈合率及三个月疼痛VAS评分改善的获益持续存在(低确定性证据)。
局限性
- 各结局的证据确定性均为低确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Recombinant human hepatocyte growth factor (HGF) plasmids are novel alternatives to salvage limbs in patients with chronic limb threatening ischaemia (CLTI). A systematic review and meta-analysis of data was conducted to assess the therapeutic efficacy of HGF plasmids in patients with CLTI. DATA SOURCES: Randomised controlled studies evaluating HGF plasmid efficacy in patients with CLTI were identified using MEDLINE, Embase, Cochrane Database of Systematic Reviews, and ClinicalTrials.gov databases. REVIEW METHODS: Meta-analyses of the reported relative risk (RR) or mean difference (MD) were conducted. Subgroup analyses were performed to determine the efficacy of HGF plasmids in cohorts excluding Buerger's disease. Certainty of evidence for each outcome was assessed. RESULTS: Seven studies (n = 655 participants) were included. Based on low certainty evidence, patients treated with HGF had a significantly higher complete ulcer healing rate (RR 1.99, 95% confidence interval [CI] 1.30 - 3.04; p = .002) than patients treated with placebo. HGF treatment was associated with reduced visual analogue scale (VAS) scores of pain severity (MD -1.56, 95% CI -2.12 - -1.00; p < .001) vs. placebo in patients with CLTI assessed at three month follow up (low certainty evidence); no significant differences were observed in major amputation (RR 0.91, 95% CI 0.48 - 1.73; p = .77) (low certainty evidence) or all cause mortality rate (RR 0.93, 95% CI 0.38 - 2.27; p = .87) (low certainty evidence) between patients treated with HGF and placebo. Low certainty evidence suggested no significant differences in change in ankle brachial index at six months (MD 0.00, 95% CI -0.09 - 0.09; p = 1.0) between patients treated with HGF and placebo. The complete ulcer healing rate and improved three month VAS scores of pain severity benefits persisted in subgroup analyses (low certainty evidence). CONCLUSION: Low certainty evidence suggested that HGF treatment is associated with an increased complete ulcer healing rate and reduced ischaemic pain in patients with CLTI.
引用
- Di X, Wang P, Li F, et al. Recombinant Human Hepatocyte Growth Factor Plasmids for Treating Patients with Chronic Limb Threatening Ischaemia: A Systematic Review and Meta-analysis. Eur J Vasc Endovasc Surg. 2024. PMID: 39019317. doi:10.1016/j.ejvs.2024.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。